Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial
AA Kirkham, E Pituskin, RB Thompson… - European Heart …, 2022 - academic.oup.com
Aims An improved understanding of the pathophysiology of trastuzumab-mediated
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …
Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer
S Nowsheen, PV Viscuse, CC O'Sullivan… - Current breast cancer …, 2017 - Springer
Abstract Purpose of Review Treatment with trastuzumab is a cornerstone of human
epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but …
epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but …
Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101–Breast): a randomized trial for the prevention of trastuzumab-associated …
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor
receptor 2–overexpressing (HER2-positive) breast cancer is dose-independent cardiac …
receptor 2–overexpressing (HER2-positive) breast cancer is dose-independent cardiac …
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
N Dempsey, A Rosenthal, N Dabas… - Breast Cancer Research …, 2021 - Springer
Purpose Despite great success as a targeted breast cancer therapy, trastuzumab use may
be complicated by heart failure and loss of left ventricular contractile function. This review …
be complicated by heart failure and loss of left ventricular contractile function. This review …
Cardiotoxicity profile of trastuzumab
SM Ewer, MS Ewer - Drug safety, 2008 - Springer
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor
receptor tyrosine kinase HER2/ErbB2. This agent has shown a highly significant antitumour …
receptor tyrosine kinase HER2/ErbB2. This agent has shown a highly significant antitumour …
Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
M Fiúza - Advances in therapy, 2009 - Springer
Introduction Although having high clinical efficacy in the treatment of human epidermal
growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been …
growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been …
[HTML][HTML] The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment
M Lin, W Xiong, S Wang, Y Li, C Hou, C Li… - Frontiers in …, 2022 - frontiersin.org
In recent years, the incidence of breast cancer has been increasing on an annual basis.
Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human …
Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human …
Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients
T Moilanen, A Jokimäki, O Tenhunen… - Journal of Cancer …, 2018 - Springer
Purpose Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart
function monitoring is recommended during the treatment which has led to growing use of …
function monitoring is recommended during the treatment which has led to growing use of …
Trastuzumab cardiotoxicity: from clinical trials to experimental studies
Epidermal growth factor receptor‐2 (HER‐2) is overexpressed in 20 to 25% of human breast
cancers, which is associated with aggressive tumour growth and poor prognosis …
cancers, which is associated with aggressive tumour growth and poor prognosis …
[HTML][HTML] Biomarkers of trastuzumab-induced cardiac toxicity in HER2-positive breast cancer patient population
A Grela-Wojewoda, M Püsküllüoğlu, B Sas-Korczyńska… - Cancers, 2022 - mdpi.com
Simple Summary Trastuzumab administered as a (neo) adjuvant therapy in radically treated
Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer patients …
Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer patients …